Allogene Therapeutics is a clinical stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer. Led by a world-class management team with significant experience in cell therapy, we are developing a pipeline of “off-the-shelf” CAR T cell therapy candidates with the goal of delivering readily available cell therapy faster, more reliably and at greater scale to more patients.
Ask Allogene Therapeutics to validate their program.
The move toward high-performance and high-value healthcare
In-depth analysis of the latest trends and solutions that improve heath outcomes, strengthen accountability, and cut costs
Actionable insights on how to drive better health outcomes at a far lower cost for your organization.
Profiles in innovative solutions and organizations that are “walking the walk” when it comes to delivering better savings, outcomes, and more
